Durability score
75/100
Valuation score
37.8/100
Momentum score
53.8/100
Market Capitalization in Cr
2348.4
Price to Book Value
3.8
PE TTM Price to Earnings
18.7
Suven Life Sciences Limited    
11 Dec 2017
184.50
-0.59%
Business Line
Suven Life Sciences has secured a product patent each from India and the US for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2029 and 2033...
Suven Life Sciences Limited is trading above it's 200 day SMA of 181.25
Suven Life Sciences Limited    
06 Dec 2017
184.50
-0.59%
Suven Life Sciences, previously in Trendlyne's focus, rises on patent win click to expand

Hyderabad-based Suven LifeSciences is a pharma firm written about by Trendlyne first in Feb 2017, when the firm won multiple patents for the treatment of Alzheimer's and other neurodegenerative diseases. The company has now received product patent recognition from Norway and Eurasia for products in the same neuro-degenerative space. The firm's share price has been rising on the news, despite the tepid market. The company has been cash positive despite significant spending on R&D - annually, Suven spends around 14% of its sales on proprietary NCE research, which has been till date, not a revenue generator.

A note of caution however remains in that Alzheimer's is a notoriously difficult disease to treat, and therapy tends to fail in large-scale usage after successful trials. One of the drugs in development by Suven, RVT-101, has released phase-2 data that was disappointing.

Suven is one of the smaller firms in the pharma space with a distinct R&D focus that has paid off so far in rising YoY revenues an EBITDA margins, which as per the most recent quarter are over 46%.

Suven Life Sciences Limited is trading below it's 30 day SMA of 197.01
Suven Life Sciences Limited    
06 Dec 2017
184.50
-0.59%
Business Line
Suven Life Sciences has secured a product patent each from Eurasia and Norway for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034 and...
Suven Life Sciences Limited is trading below it's 30 day SMA of 197.01
Suven Life Sciences Limited    
16 Nov 2017
184.50
-0.59%
Business Standard
The patents are valid till 2032, 2030 and 2034, respectively, the company said in a BSE filing
Suven Life Sciences Limited    
11 Nov 2017
184.50
-0.59%
Business Line
Suven Life Sciences reported a 19.5 per cent increase in net profit to Rs 31.74 crore for the second quarter ended September 30. The company had posted a net profit of Rs 26.55 crore in the same...
Suven Life Sciences Limited is trading above it's 200 day SMA of 181.25
Suven Life Sciences Limited    
10 Oct 2017
184.50
-0.59%
Business Line
Shares of Suven Life Sciences surged over 7 per cent in Tuesday's trade as the company has received a patent from New Zealand for a drug used for the treatment of neuro-degenerative diseases. The...
Suven Life Sciences Limited    
25 Sep 2017
184.50
-0.59%
Suven Life Sciences gets neuro patent from India, Japan
Suven Life Sciences gets neuro patent from India, Japan
livemint
Suven Life Sciences has been granted a patent each by India and Japan for a drug used in the treatment of neuro-degenerative diseases
Suven Life Sciences Limited    
21 Aug 2017
184.50
-0.59%
Business Line
Suven Life Sciences has secured a product patent in Japan to be used for developing therapeutic agents that are useful in the treatment of neuro-degenerative diseases. Suven Life said in a BSE...
Suven Life Sciences Limited is trading above it's 200 day SMA of 181.25
Suven Life Sciences Limited    
17 Aug 2017
184.50
-0.59%
Business Line
Suven Life Sciences on Thursday informed the exchanges that it has secured process patents from Europe, Japan and New Zealand for new chemical entities (NCEs) used for the treatment of disorders...
Suven Life Sciences Limited    
10 Jul 2017
184.50
-0.59%
Business Line
Suven Life Sciences has received product patents from Israel, Macau and South Korea for New Chemical Entities (NCEs) used in the treatment of disorders associated with neurodegenerative diseases.
default
Suven Life Sciences Limited is trading above it's 200 day SMA of 181.25
  • Stock Price (200.50) crossed above 50 Day SMA (194.83) on 21 November, 2017
  • Stock Price (198.00) crossed below 30 Day SMA (201.43) on 08 November, 2017
  • Month Change by 21.9% (Crossed threshold 20%) on 31 October, 2017
  • Month Change by 16.51% (Crossed threshold 15%) on 25 October, 2017
  • Week Change by 11.72% (Crossed threshold 10%) on 19 October, 2017
More triggered alerts
Ex-Date Dividend Amount Dividend Type Record Date
Feb. 8, 20171.00INTERIM-
March 14, 20161.00SPECIAL-
March 14, 20161.00INTERIM-
July 23, 20150.60--
July 24, 20142.00SPECIAL-
All dividends by SUVEN
Ex-Date Dividend Bonus Ratio Record Date
March 23, 20071:1April 2, 2007
All bonuses by SUVEN